News & Updates

SGLT2 inhibitors score big, this time in gout
SGLT2 inhibitors score big, this time in gout
22 Jun 2023 byElvira Manzano

Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.

SGLT2 inhibitors score big, this time in gout
22 Jun 2023
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
19 Jun 2023

People with diabetes mellitus (DM) have a higher risk of pancreatic cancer than those without DM, reveals a recent study. Among diabetic individuals, those with new-onset DM show a greater pancreatic cancer risk than those with long-standing DM.

New-onset vs long-standing diabetes tied to higher pancreatic cancer risk
19 Jun 2023
Family-based treatment helps with weight loss in children with overweight, obesity
Family-based treatment helps with weight loss in children with overweight, obesity
17 Jun 2023

The implementation of family-based treatment for overweight or obesity in paediatric primary care settings has demonstrated success, with a recent study showing that the treatment led to improved weight outcomes.

Family-based treatment helps with weight loss in children with overweight, obesity
17 Jun 2023